S&P 500   3,914.30 (-0.24%)
DOW   31,321.74 (-0.53%)
QQQ   291.07 (-0.02%)
AAPL   137.52 (-2.34%)
MSFT   253.57 (-0.20%)
FB   192.44 (+0.10%)
GOOGL   2,211.34 (-1.19%)
AMZN   2,163.53 (+0.99%)
TSLA   714.73 (+0.69%)
NVDA   173.73 (+2.57%)
BABA   88.32 (+1.16%)
NIO   16.77 (+5.94%)
AMD   98.54 (+2.35%)
CGC   5.95 (+6.44%)
MU   70.28 (-1.08%)
T   20.15 (-0.40%)
GE   75.78 (+0.77%)
F   12.99 (+1.64%)
DIS   103.75 (-0.53%)
AMC   12.95 (+1.49%)
PFE   50.38 (-0.04%)
PYPL   81.51 (+5.61%)
NFLX   185.04 (+4.43%)
S&P 500   3,914.30 (-0.24%)
DOW   31,321.74 (-0.53%)
QQQ   291.07 (-0.02%)
AAPL   137.52 (-2.34%)
MSFT   253.57 (-0.20%)
FB   192.44 (+0.10%)
GOOGL   2,211.34 (-1.19%)
AMZN   2,163.53 (+0.99%)
TSLA   714.73 (+0.69%)
NVDA   173.73 (+2.57%)
BABA   88.32 (+1.16%)
NIO   16.77 (+5.94%)
AMD   98.54 (+2.35%)
CGC   5.95 (+6.44%)
MU   70.28 (-1.08%)
T   20.15 (-0.40%)
GE   75.78 (+0.77%)
F   12.99 (+1.64%)
DIS   103.75 (-0.53%)
AMC   12.95 (+1.49%)
PFE   50.38 (-0.04%)
PYPL   81.51 (+5.61%)
NFLX   185.04 (+4.43%)
S&P 500   3,914.30 (-0.24%)
DOW   31,321.74 (-0.53%)
QQQ   291.07 (-0.02%)
AAPL   137.52 (-2.34%)
MSFT   253.57 (-0.20%)
FB   192.44 (+0.10%)
GOOGL   2,211.34 (-1.19%)
AMZN   2,163.53 (+0.99%)
TSLA   714.73 (+0.69%)
NVDA   173.73 (+2.57%)
BABA   88.32 (+1.16%)
NIO   16.77 (+5.94%)
AMD   98.54 (+2.35%)
CGC   5.95 (+6.44%)
MU   70.28 (-1.08%)
T   20.15 (-0.40%)
GE   75.78 (+0.77%)
F   12.99 (+1.64%)
DIS   103.75 (-0.53%)
AMC   12.95 (+1.49%)
PFE   50.38 (-0.04%)
PYPL   81.51 (+5.61%)
NFLX   185.04 (+4.43%)
S&P 500   3,914.30 (-0.24%)
DOW   31,321.74 (-0.53%)
QQQ   291.07 (-0.02%)
AAPL   137.52 (-2.34%)
MSFT   253.57 (-0.20%)
FB   192.44 (+0.10%)
GOOGL   2,211.34 (-1.19%)
AMZN   2,163.53 (+0.99%)
TSLA   714.73 (+0.69%)
NVDA   173.73 (+2.57%)
BABA   88.32 (+1.16%)
NIO   16.77 (+5.94%)
AMD   98.54 (+2.35%)
CGC   5.95 (+6.44%)
MU   70.28 (-1.08%)
T   20.15 (-0.40%)
GE   75.78 (+0.77%)
F   12.99 (+1.64%)
DIS   103.75 (-0.53%)
AMC   12.95 (+1.49%)
PFE   50.38 (-0.04%)
PYPL   81.51 (+5.61%)
NFLX   185.04 (+4.43%)
NASDAQ:MDXG

MiMedx Group (MDXG) Stock Forecast, Price & News

$3.61
-0.03 (-0.82%)
(As of 05/19/2022 01:49 PM ET)
Add
Compare
Today's Range
$3.59
$3.71
50-Day Range
$3.29
$5.00
52-Week Range
$3.27
$8.69
Volume
8,106 shs
Average Volume
611,814 shs
Market Capitalization
$409.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.92
30 days | 90 days | 365 days | Advanced Chart
Receive MDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

MiMedx Group logo

About MiMedx Group

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDXG
Employees
811
Year Founded
N/A

Sales & Book Value

Annual Sales
$258.61 million
Book Value
($0.07) per share

Profitability

Net Income
$-10.28 million
Pretax Margin
-4.71%

Debt

Price-To-Earnings

Miscellaneous

Free Float
90,909,000
Market Cap
$409.19 million
Optionable
Optionable

Company Calendar

Last Earnings
5/03/2022
Today
5/19/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.49 out of 5 stars

Medical Sector

144th out of 1,418 stocks

Surgical & Medical Instruments Industry

18th out of 137 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -













MiMedx Group (NASDAQ:MDXG) Frequently Asked Questions

Is MiMedx Group a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MiMedx Group stock.
View analyst ratings for MiMedx Group
or view top-rated stocks.

When is MiMedx Group's next earnings date?

MiMedx Group is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for MiMedx Group
.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) released its quarterly earnings data on Tuesday, May, 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.01. During the same quarter in the previous year, the business posted ($0.09) EPS.
View MiMedx Group's earnings history
.

What guidance has MiMedx Group issued on next quarter's earnings?

MiMedx Group updated its FY 2022 earnings guidance on Monday, March, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $266.40 million-$273.60 million, compared to the consensus revenue estimate of $267.30 million.

What price target have analysts set for MDXG?

2 Wall Street analysts have issued 12-month price objectives for MiMedx Group's stock. Their forecasts range from $8.50 to $23.00. On average, they expect MiMedx Group's stock price to reach $15.75 in the next year. This suggests a possible upside of 336.3% from the stock's current price.
View analysts' price targets for MiMedx Group
or view top-rated stocks among Wall Street analysts.

Who are MiMedx Group's key executives?
MiMedx Group's management team includes the following people:
  • Mr. Peter Martin Carlson CPA, Chief Financial Officer (Age 58, Pay $787.81k)
  • Mr. William F. Hulse IV, Gen. Counsel & Chief Admin. Officer (Age 48, Pay $733.69k)
  • Dr. Rohit Kashyap Ph.D., Pres of Wound Care & Surgical (Age 51, Pay $741.29k)
  • Dr. Robert Benjamin Stein M.D., Ph.D., Pres of Regenerative Medicine & Biologics Innovation (Age 71, Pay $731.25k)
  • Mr. Timothy R. Wright MBA, CEO & Director (Age 64)
  • Mr. Scott M. Turner, Sr. VP of Operations & Procurement (Age 57)
  • Mr. William L. Phelan, Sr. VP & Chief Accounting Officer
  • Mr. John J. Howarth, Sr. VP of Investor Relations
  • Mr. Mark P. Graves, Sr. VP & Chief Compliance Officer (Age 56)
  • Hilary Dixon, VP of Investor Relations & Corp. Strategic Communications
What is MiMedx Group's stock symbol?

MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.42%), Vanguard Group Inc. (4.01%), State Street Corp (3.89%), Richmond Brothers Inc. (2.25%), Federated Hermes Inc. (1.52%) and Northern Trust Corp (0.87%). Company insiders that own MiMedx Group stock include Mark Graves, Peter M Carlson, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan.
View institutional ownership trends for MiMedx Group
.

Which institutional investors are selling MiMedx Group stock?

MDXG stock was sold by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Citigroup Inc., Royal Bank of Canada, Northern Trust Corp, Raymond James & Associates, Richmond Brothers Inc., State Board of Administration of Florida Retirement System, and Group One Trading L.P.. Company insiders that have sold MiMedx Group company stock in the last year include Mark Graves, Peter M Carlson, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse, and William Lawrence Phelan.
View insider buying and selling activity for MiMedx Group
or view top insider-selling stocks.

Which institutional investors are buying MiMedx Group stock?

MDXG stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., State Street Corp, Renaissance Technologies LLC, Fisher Asset Management LLC, ClariVest Asset Management LLC, Goldman Sachs Group Inc., Vanguard Group Inc., and Isthmus Partners LLC.
View insider buying and selling activity for MiMedx Group
or or view top insider-buying stocks.

How do I buy shares of MiMedx Group?

Shares of MDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MiMedx Group's stock price today?

One share of MDXG stock can currently be purchased for approximately $3.61.

How much money does MiMedx Group make?

MiMedx Group has a market capitalization of $409.19 million and generates $258.61 million in revenue each year. The company earns $-10.28 million in net income (profit) each year or ($0.170010) on an earnings per share basis.

How many employees does MiMedx Group have?

MiMedx Group employs 811 workers across the globe.

What is MiMedx Group's official website?

The official website for MiMedx Group is www.mimedx.com.

How can I contact MiMedx Group?

MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The company can be reached via phone at (770) 651-9100, via email at [email protected], or via fax at 678-384-6741.

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.